Categories Analysis, Consumer, Retail, U.S. Markets News
Preview: Alaska Airlines to report Q4 earnings on Jan 24
Alaska Airlines (ALK) is scheduled to report fourth-quarter results after the closing bell on Thursday, January 24. Analysts expect the company to post earnings of 73 cents per share on revenues of $2.06 billion.
The airliner had topped profit estimates during the prior three quarters, and yet the bottom-line had declined year-over-year during each of them. Analysts expect the trend to continue into the fourth quarter, primarily due to higher fuel prices and unimpressive load factor.
Though jet fuel prices declined by the end of the year, it was still higher than the levels witnessed same time last year. Alaska management had projected jet fuel price for the fourth quarter at $2.35 per gallon.
Meanwhile, the stagnant load factor (an important metric for airline companies that map the percentage of seats occupied by passengers) over the past three quarters may primarily be attributed to capacity overexpansion.
Keeping aside these weaknesses, Alaska Airlines actually had a strong holiday quarter that saw robust traffic during the Thanksgiving weekend. This complemented by favorable pricing and lower tax rates are expected to boost the company’s results during the fourth quarter.
In the to-be-reported quarter, ALK anticipates revenue per available seat mile (RASM) between 12.82 cents and 12.84 cents, suggesting a 5% growth from last year.
ALK shares have traded mostly sideways throughout the trailing 52 weeks and are currently down 8.2%.
Last week, bigger rivals United Airlines (UAL) and Delta Air Lines (DAL) had reported earnings results. United shares jumped 5% after the company surpassed analysts’ estimates, while Delta shares slipped after it missed the expectations on the outlook.
We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on